Astec LifeSciences [ASTEC] vs UPL [UPLPP] Detailed Stock Comparison
Astec LifeSciences
NSE
Loading...
UPL
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Astec LifeSciences wins in 3 metrics, UPL wins in 15 metrics, with 0 ties. UPL appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Astec LifeSciences | UPL | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 399.52 | 3.00 | UPL |
| Price-to-Book Ratio | 6.77 | 1.63 | UPL |
| Debt-to-Equity Ratio | 235.96 | 105.06 | UPL |
| PEG Ratio | -22.88 | -0.05 | Astec LifeSciences |
| EV/EBITDA | -66.76 | 13.32 | Astec LifeSciences |
| Profit Margin (TTM) | -31.78% | 0.09% | UPL |
| Operating Margin (TTM) | -24.68% | 13.51% | UPL |
| EBITDA Margin (TTM) | N/A | 13.51% | N/A |
| Return on Equity | -57.34% | 2.01% | UPL |
| Return on Assets (TTM) | -15.29% | 0.86% | UPL |
| Free Cash Flow (TTM) | $-302.21M | $84.56B | UPL |
| Dividend Yield | N/A | 0.69% | N/A |
| 1-Year Return | -30.00% | 104.96% | UPL |
| Price-to-Sales Ratio (TTM) | 4.48 | 1.38 | UPL |
| Enterprise Value | $21.43B | $724.61B | UPL |
| EV/Revenue Ratio | 5.32 | 1.61 | UPL |
| Gross Profit Margin (TTM) | 29.86% | 54.76% | UPL |
| Revenue per Share (TTM) | $206 | $570 | UPL |
| Earnings per Share (Diluted) | $-64.81 | $-0.74 | UPL |
| Beta (Stock Volatility) | 0.06 | 0.83 | Astec LifeSciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Astec LifeSciences vs UPL Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Astec LifeSciences | -1.13% | -2.46% | -12.92% | 18.26% | -4.29% | -17.65% |
| UPL | 0.00% | 0.00% | 16.86% | 21.84% | 96.43% | 129.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Astec LifeSciences | -30.00% | -56.78% | -35.28% | 222.96% | 907.65% | 881.41% |
| UPL | 104.96% | 104.96% | 104.96% | 104.96% | 104.96% | 104.96% |
Performance & Financial Health Analysis: Astec LifeSciences vs UPL
| Metric | ASTEC | UPLPP |
|---|---|---|
| Market Information | ||
| Market Cap | ₹18.05B | ₹622.77B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 77,339 | 1,096 |
| 90 Day Avg. Volume | 51,792 | 5,063 |
| Last Close | ₹801.00 | ₹516.50 |
| 52 Week Range | ₹634.60 - ₹1,333.50 | ₹216.20 - ₹563.85 |
| % from 52W High | -39.93% | -8.40% |
| All-Time High | ₹2,288.80 (Nov 14, 2022) | ₹563.85 (Jul 30, 2025) |
| % from All-Time High | -65.00% | -8.40% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.31% | 0.10% |
| Quarterly Earnings Growth | 0.31% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | -0.32% | 0.00% |
| Operating Margin (TTM) | -0.25% | 0.14% |
| Return on Equity (TTM) | -0.57% | 0.02% |
| Debt to Equity (MRQ) | 235.96 | 105.06 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹119.70 | ₹318.92 |
| Cash per Share (MRQ) | ₹0.29 | ₹51.99 |
| Operating Cash Flow (TTM) | ₹-705,500,000 | ₹70.93B |
| Levered Free Cash Flow (TTM) | ₹-1,347,524,000 | ₹7.59B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.69% |
| Last 12-Month Dividend | ₹0.00 | ₹3.00 |
Valuation & Enterprise Metrics Analysis: Astec LifeSciences vs UPL
| Metric | ASTEC | UPLPP |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 399.52 | 3.00 |
| Forward P/E | 20.05 | N/A |
| PEG Ratio | -22.88 | -0.05 |
| Price to Sales (TTM) | 4.48 | 1.38 |
| Price to Book (MRQ) | 6.77 | 1.63 |
| Market Capitalization | ||
| Market Capitalization | ₹18.05B | ₹622.77B |
| Enterprise Value | ₹21.43B | ₹724.61B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.32 | 1.61 |
| Enterprise to EBITDA | -66.76 | 13.32 |
| Risk & Other Metrics | ||
| Beta | 0.06 | 0.83 |
| Book Value per Share (MRQ) | ₹119.70 | ₹318.92 |
Financial Statements Comparison: Astec LifeSciences vs UPL
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ASTEC | UPLPP |
|---|---|---|
| Revenue/Sales | ₹910.82M | ₹92.16B |
| Cost of Goods Sold | ₹638.84M | ₹41.69B |
| Gross Profit | ₹271.98M | ₹50.47B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-224.80M | ₹7.64B |
| EBITDA | ₹-104.80M | ₹14.78B |
| Pre-Tax Income | ₹-330.18M | ₹-1.90B |
| Income Tax | ₹94,000 | ₹-140.00M |
| Net Income (Profit) | ₹-330.27M | ₹-1.76B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ASTEC | UPLPP |
|---|---|---|
| Cash & Equivalents | ₹5.75M | ₹94.78B |
| Total Current Assets | ₹3.41B | ₹396.61B |
| Total Current Liabilities | ₹3.66B | ₹285.69B |
| Long-Term Debt | ₹2.80B | ₹192.56B |
| Total Shareholders Equity | ₹2.35B | ₹378.26B |
| Retained Earnings | ₹1.41B | ₹208.68B |
| Property, Plant & Equipment | ₹317.38M | ₹94.31B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ASTEC | UPLPP |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ASTEC | UPLPP |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 77,339 | 1,096 |
| Average Daily Volume (90 Day) | 51,792 | 5,063 |
| Shares Outstanding | 19.76M | 844.43M |
| Float Shares | 6.74M | 563.84M |
| % Held by Insiders | 0.84% | 0.00% |
| % Held by Institutions | 0.07% | 0.17% |
Dividend Analysis & Yield Comparison: Astec LifeSciences vs UPL
| Metric | ASTEC | UPLPP |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹3.00 |
| Last 12-Month Dividend Yield | N/A | 0.69% |
| 3-Year Avg Annual Dividend | ₹1.00 | ₹1.00 |
| 3-Year Avg Dividend Yield | 0.10% | 0.69% |
| 3-Year Total Dividends | ₹3.00 | ₹3.00 |
| Ex-Dividend Date | Jul 21, 2023 | Jul 11, 2025 |